PHP
XENT

Parkman Healthcare Partners’s Intersect ENT, Inc XENT Stock Holding History

Parkman Healthcare Partners’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-165,923
Closed -$1.97M – 88
2020
Q1 		$1.97M Buy
165,923
+40,423
+32% +$896K 0.91% 40
2019
Q4 		$3.13M Buy
+125,500
New +$2.54M 0.9% 38

Other funds holding XENT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parkman Healthcare Partners's XENT Position: Q2 2020 in Review

Parkman Healthcare Partners sold out of Intersect ENT, Inc (XENT) in Q2 2020, closing a stake of 165,923 shares — an estimated $1.97M sold.

Parkman Healthcare Partners first reported a position in XENT in Q4 2019 and held it in 2 quarters. The position peaked at $3.13M in Q4 2019. 108 funds tracked by Wall St. Rank hold XENT as of Q2 2020.

  • Parkman Healthcare Partners reported no remaining Intersect ENT, Inc position as of Q2 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 165,923 Intersect ENT, Inc shares in Q2 2020, an estimated $1.97M.
  • Parkman Healthcare Partners first reported a position in Intersect ENT, Inc in Q4 2019 and held it in 2 quarters.
  • Parkman Healthcare Partners's Intersect ENT, Inc position peaked at $3.13M in Q4 2019.
  • 108 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2020.

Based on Parkman Healthcare Partners's 13F filing for Q2 2020, filed 13 Aug 2020.